Trial Profile
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH2
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Mar 2023 Results of post hoc analysis from REACH2 and REACH3 trials assessing the ruxolitinib efficacy in patients with dermatologic manifestations of graft-versus-host disease, presented at the American Academy of Dermatology annual Meeting 2023.
- 06 Mar 2023 According to Incyte Media Release, A Post Hoc Analysis of the Phase 3 REACH2 and REACH3 Studies will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting
- 24 Feb 2023 Results of exploratory analysis were published in the Blood.